Coudl Ozempic and Wegovy Lead to Blindness? EMA Investigates Potential Risks
GLP-1 receptor agonists, such as semaglutide, have revolutionized the treatment of type 2 diabetes by improving blood sugar control. More recently, their use has been extended to obesity treatment due to their ability to reduce appetite and promote weight loss. drugs like Ozempic and Wegovy have soared in popularity for thes benefits, but they are now under scrutiny due to reported side effects, both known and emerging.
The European Medicines Agency (EMA) has launched an investigation to determine whether semaglutide increases the risk of developing anterior ischemic optic neuropathy (AION), a rare eye condition that can cause blindness and visual field loss without other symptoms. This review follows the publication of two Danish studies suggesting a potential link between these drugs and an elevated risk of AION in patients with diabetes.
A parallel study published in Nature Medicine analyzed data from 2.4 million American patients, revealing that GLP-1 receptor agonists could be associated with up to 42 diseases, including Alzheimer’s and various types of cancer. additionally, the study identified risks for 19 other conditions, such as arthritic and kidney disorders.
| Key Findings |
|——————|
| Increased risk of AION in diabetes patients |
| Potential link to 42 diseases, including Alzheimer’s and cancer |
| Risks for 19 conditions, such as arthritis and kidney disorders |
Experts caution that while these findings are notable, they should be interpreted carefully, as the studies are observational. The EMA will evaluate all available data, including clinical trials, to determine whether updates to semaglutide usage recommendations are necessary.
In the meantime, patients are advised to continue their treatments as prescribed and consult healthcare professionals with any concerns.
For the latest updates on this developing story, follow us on our WhatsApp channel.
This article is based on information from the original source and additional research.
Based on the provided web search results and the article “Could Ozempic and Wegovy Lead to Blindness? EMA Investigates Potential Risks,” here’s a summary:
- GLP-1 Receptor Agonists: Semaglutide (brand names: Ozempic, Wegovy), along with other GLP-1 receptor agonists, are medications used to manage type 2 diabetes and, more recently, treat obesity [1[1[1[1, 2].
- Anterior Ischemic Optic Neuropathy (AION) Risk: The European Medicines Agency (EMA) is investigating whether semaglutide increases the risk of developing AION, a rare eye condition that can cause blindness and visual field loss, based on two Danish studies suggesting a potential link between these drugs and AION in diabetes patients [[2], Article].
- Association with Various Diseases: A study published in Nature Medicine found that GLP-1 receptor agonists could be associated with up to 42 diseases, including Alzheimer’s and various types of cancer, as well as risks for 19 other conditions such as arthritis and kidney disorders [[2], Article].
- Temporary Advice: While the EMA evaluates all available data, including clinical trials, to determine whether updates to semaglutide usage recommendations are necessary, patients are advised to continue their treatments as prescribed and consult healthcare professionals with any concerns.
